±¸°­ºØÇØÁ¤ ½ÃÀå : ºÎ¹®º°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2024-2032³â)
Orally Disintegrating Tablet Market, By Drug Type, By Indication, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
»óǰÄÚµå : 1555504
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2024³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 390 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,612,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,598,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 8,017,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

±¸°­ºØÇØÁ¤(Orally Disintegrating Tablet) ½ÃÀå ±Ô¸ð´Â 2023³â 131¾ï 2,312¸¸ ´Þ·¯¿´À¸¸ç, 2024³âºÎÅÍ 2032³â±îÁö CAGR 8.1%·Î ÃßÀÌÇϸç È®´ë µÉ °ÍÀ¸·Î ¿¹»ó

±¸°­ºØÇØÁ¤ ½ÃÀå-½ÃÀå ¿ªÇÐ

¹ÙÀÌ¿À °¡¿ë¼º Çâ»ó°ú ÆíÀǼº Çâ»óÀÌ ½ÃÀå ¼ö¿ä¸¦ ÃËÁøÇÒ Àü¸Á

ODT´Â ƯÁ¤ ¾àÁ¦ÀÇ »ýüÀÌ¿ë·üÀ» Çâ»ó½ÃŰ°í º¸´Ù È¿°úÀûÀ¸·Î ¸¸µé ¼ö ÀÖ½À´Ï´Ù. ÀÌ´Â ½Å¼ÓÇÑ ÀÛ¿ë ¹ßÇöÀ» ÇÊ¿ä·Î ÇÏ´Â ¾àÁ¦¿¡ ƯÈ÷ À¯¿ëÇÕ´Ï´Ù. ODT´Â ¼Ò¾Æ ¹× ³ëÀÎ ÀÇ·á»Ó¸¸ ¾Æ´Ï¶ó Á¤½Å °Ç°­, ¾Ë·¹¸£±â, ÅëÁõ °ü¸® µî ´Ù¾çÇÑ Ä¡·á ºÐ¾ß¿¡¼­ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±¤¹üÀ§ÇÑ ¿ëµµ°¡ ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ±âÁ¸ÀÇ Á¤Á¦º¸´Ù ODT°¡ »ç¿ëÇϱ⠽±°í ¹°ÀÌ ÇÊ¿äÇÏÁö ¾Ê±â ¶§¹®¿¡ ȯÀÚ´Â ODT¸¦ ¼±È£ÇÕ´Ï´Ù. ȯÀÚÀÇ ÄÄÇöóÀ̾𽺰¡ Çâ»óµÇ¸é Ä¡·á ¼ºÀûµµ Çâ»óµÇ°í ³ª¾Æ°¡ ¼ö¿äµµ ³ô¾ÆÁý´Ï´Ù.

¶ÇÇÑ ODT´Â ±âÁ¸ÀÇ Á¤Á¦¿Í ĸ½¶À» »ïŰ±â°¡ ¾î·Á¿î ȯÀÚ¿¡°Ô ½Ç¿ëÀûÀÎ ¼Ö·ç¼ÇÀÔ´Ï´Ù. ¿©±â¿¡´Â ¼Ò¾Æ, ³ëÀÎ ¹× ƯÁ¤ º´¸®ÇÐÀ» °¡Áø ȯÀÚ°¡ Æ÷ÇԵ˴ϴÙ. ¹°ÀÌ ÇÊ¿ä¾ø´Â Åõ¿©ÀÇ ¿ëÀ̼ºÀº ȯÀÚÀÇ ÄÄÇöóÀ̾𽺠Çâ»ó¿¡ ±â¿©ÇÕ´Ï´Ù. Á¤Á¦ Á¦Á¦ ±â¼úÀÇ Çõ½ÅÀ¸·Î ODTÀÇ ¸À, ¾ÈÁ¤¼º ¹× È¿´ÉÀÌ Çâ»óµÇ¾ú½À´Ï´Ù. Á¦Á¶ °øÁ¤ÀÇ Áøº¸´Â º¸´Ù È¿°úÀûÀ̰í ȯÀÚ Ä£È­ÀûÀÎ ODT¸¦ °¡´ÉÇÏ°Ô Çß½À´Ï´Ù.

±¸°­ºØÇØÁ¤ ½ÃÀå-ÁÖ¿ä ÀλçÀÌÆ®

¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ® ºÐ¼®¿¡ µû¸£¸é ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2032³â) µ¿¾È ¾à 8.1%ÀÇ CAGR·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

¾àÁ¦ À¯Çüº° ¼¼ºÐÈ­¿¡ µû¸£¸é, ¾Ë·¹¸£±â Áúȯ Áõ°¡·Î ÀÎÇØ Ç׾˷¹¸£±â ¾àÁ¦ ºÎ¹®Àº 2023³â¿¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÀûÀÀÁõº°·Î´Â ½ÉÇ÷°ü Ä¡·á¿¡ À־ ODTÀÇ ¸·´ëÇÑ ¼ö¿ä·ÎºÎÅÍ, ½ÉÇ÷°ü Áúȯ ºÐ¾ß°¡ 2023³âÀÇ ÁÖ¿ä ÀûÀÀÁõÀ̾ú½À´Ï´Ù.

À¯Åë ä³Îº°·Î´Â º´¿ø¿¡¼­ ODT ¼ö¿ä°¡ ³ô±â ¶§¹®¿¡ º´¿ø ¾à±¹ÀÌ 2023³â À¯Åë ä³ÎÀÇ ÅéÀ̾ú½À´Ï´Ù.

Áö¿ªº°·Î´Â ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡·Î ºÏ¹Ì°¡ 2023³â °¡Àå ¸¹Àº ¼öÀÍÀ» âÃâÇß½À´Ï´Ù.

±¸°­ºØÇØÁ¤ ½ÃÀå-¼¼ºÐÈ­ ºÐ¼® :

±¸°­ºØÇØÁ¤ ¼¼°è ½ÃÀåÀº ¾àÁ¦ À¯Çü, ÀûÀÀÁõ, À¯Åë ä³Î, Áö¿ª¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù.

ÀǾàǰ À¯Çüº°·Î´Â Ç×Á¤½Åº´Á¦, Ç×°£ÁúÁ¦, Ç×°íÇ÷¾ÐÁ¦, Ç׺ҾÈÁ¦, Ç׾˷¹¸£±âÁ¦, ¾ç¼ºÀÚ ÆßÇÁ ¾ïÁ¦Á¦ µî 7°¡Áö·Î ºÐ·ùµË´Ï´Ù. ½ÃÀåÀ» µ¶Á¡ÇÏ´Â °ÍÀº Ç× ¾Ë·¹¸£±â ¾àÁ¦ÀÔ´Ï´Ù. ¾Ë·¹¸£±â ÁúȯÀÇ À¯º´·üÀÌ ³ô¾Æ Ç׾˷¹¸£±â Á¤Á¦ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

½ÃÀåÀº ÀûÀÀÁõº°·Î ½Å°æ Áúȯ, ½ÉÇ÷°üÁúȯ, ¼ÒÈ­±âÁúȯ, ¾Ë·¹¸£±âÁúȯ µî 5°¡Áö·Î ºÐ·ùµË´Ï´Ù. ½ÉÇ÷°ü Áúȯ ºÐ¾ß°¡ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. ODT´Â ¸ðµç ½ÉÇ÷°ü ÁúȯÀÇ Ä¡·á¿¡ ³Î¸® »ç¿ëµÇ¸ç, ÀÌ´Â ÀÌ ºÐ¾ßÀÇ ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù.

½ÃÀåÀº À¯Åë ä³Î¿¡ µû¶ó º´¿ø ¾à±¹, ¿Â¶óÀÎ ¾à±¹ ¹× ±âŸ ¼¼ °¡Áö·Î ºÐ·ùµË´Ï´Ù. º´¿ø ¾à±¹ ºÐ¾ß´Â ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖÀ¸¸ç ¿¹Ãø ±â°£ µ¿¾È¿¡µµ ³ôÀº ¿ìÀ§¸¦ À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿Â¶óÀÎ ¾à±¹ ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

±¸°­ºØÇØÁ¤ ½ÃÀå : Áö¿ªº° ÀλçÀÌÆ®

Áö¿ªÀûÀ¸·Î´Â ºÏ¹Ì, ³²¹Ì, À¯·´, ¾Æ½Ã¾Æ ÅÂÆò¾ç, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ °¢ Áö¿ªÀ¸·Î ÆÛÁ® ÀÖ½À´Ï´Ù. ºÏ¹Ì´Â ODT ¼¼°è ½ÃÀå¿¡¼­ Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖÀ¸¸ç, ±× ÁÖµÈ ÀÌÀ¯´Â °í±Þ °Ç°­ °ü¸® ÀÎÇÁ¶ó¿Í ¸¸¼º ÁúȯÀÇ ³ôÀº À¯º´·ü¿¡ ÀÖ½À´Ï´Ù. ¾Æ½Ã¾Æ ÅÂÆò¾çÀº °Ç°­ °ü¸® Á¢±Ù¼ºÀÌ Çâ»óµÇ°í ¸¸¼º ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡Çϰí ȯÀÚ Àα¸°¡ ¸¹±â ¶§¹®¿¡ ODT ½ÃÀåÀÌ ±Þ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. Àεµ¿Í Áß±¹°ú °°Àº ±¹°¡¿¡¼­´Â ³ôÀº Àα¸ ¹Ðµµ¿Í ÀÇ·á ¿ä±¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå ±âȸ°¡ Ä¿Áö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ±¹³» Á¦¾àȸ»ç°¡ ODT Á¦Á¦¸¦ °³¹ßÇÏ´Â µ¿Çâµµ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.

±¸°­ºØÇØÁ¤ ½ÃÀå-°æÀï ±¸µµ :

±¸°­ºØÇØÁ¤(ODT) ½ÃÀåÀº °æÀïÀÌ Ä¡¿­ÇÏ¿© ¿©·¯ ÁÖ¿ä ±â¾÷µéÀÌ ÁøÀÔÇϰí ÀÖÀ¸¸ç ÇöÀç ÁøÇà ÁßÀÎ °³¹ßÀÌ ±× Á¤¼¼¸¦ Çü¼ºÇϰí ÀÖ½À´Ï´Ù. ½ÃÀå °¢»ç´Â ¹Ì°¢ ¸¶½ºÅ·À» °³¼±ÇÏ°í ºØ±« ½Ã°£À» ´ÜÃàÇÑ »õ·Î¿î ODT Á¦Á¦¸¦ °³¹ßÇϰí ÀÖ½À´Ï´Ù. ºÎÇüÁ¦ ±â¼ú°ú Á¤Á¦ ¸ÅÆ®¸¯½º ¼³°èÀÇ Çõ½ÅÀº ȯÀÚÀÇ Àü¹ÝÀûÀÎ »ç¿ë°¨À» Çâ»ó½Ãŵ´Ï´Ù. ÁÖ¿ä Á¦¾à ȸ»ç´Â ¾Æ½Ã¾Æ ÅÂÆò¾ç ¹× ³²¹Ì¿Í °°Àº ½ÅÈï ½ÃÀå¿¡¼­ ODT Á¦Ç°ÀÇ È®´ë¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ È®´ë´Â °Ç°­ °ü¸®¿¡ ´ëÇÑ Á¢±ÙÀÌ È®´ëµÇ°í ȯÀÚ¿¡°Ô ģȭÀûÀÎ ¾àÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ´Â °ÍÀÌ ¹è°æ¿¡ ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ±¸°­ºØÇØÁ¤ ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ±¸°­ºØÇØÁ¤-ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå ±¸°­ºØÇØÁ¤ »ê¾÷ ¿¬±¸

Á¦5Àå ±¸°­ºØÇØÁ¤ ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå ±¸°­ºØÇØÁ¤ ½ÃÀå »óȲ

Á¦7Àå ±¸°­ºØÇØÁ¤ ½ÃÀå-¾àÁ¦ À¯Çüº°

Á¦8Àå ±¸°­ºØÇØÁ¤ ½ÃÀå-ÀûÀÀÁõº°

Á¦9Àå ±¸°­ºØÇØÁ¤ ½ÃÀå-À¯Åë ä³Îº°

Á¦10Àå ±¸°­ºØÇØÁ¤ ½ÃÀå-Áö¿ª

Á¦11Àå ÁÖ¿ä º¥´õ ºÐ¼®-±¸°­ºØÇØÁ¤ »ê¾÷

Á¦12Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

LYJ
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Orally Disintegrating Tablet Market size was valued at USD 13,123.12 Million in 2023, expanding at a CAGR of 8.1% from 2024 to 2032.

An Orally Disintegrating Tablet (ODT) is a type of medication that is designed to dissolve quickly in the mouth without needing water. This can be particularly useful for people who have difficulty swallowing traditional tablets or capsules, such as children or elderly patients.

Orally Disintegrating Tablet Market- Market Dynamics

Increasing improved bioavailability and convenience to use are expected to propel market demand

ODTs can enhance the bioavailability of certain drugs, making them more effective. This is particularly beneficial for medications that require rapid onset of action. ODTs are increasingly used in a variety of therapeutic areas beyond just pediatric and geriatric care, including mental health, allergies, and pain management. This broader application helps drive market growth. Patients often prefer ODTs over traditional tablets due to their ease of use and the reduced need for water. Increased patient compliance can lead to better therapeutic outcomes and, subsequently, higher demand.

Furthermore, ODTs offer a practical solution for patients who have difficulty swallowing traditional tablets or capsules. This includes children, elderly individuals, and those with certain medical conditions. The ease of administration without needing water contributes to higher patient compliance. Innovations in tablet formulation technologies have improved the taste, stability, and efficacy of ODTs. Advances in manufacturing processes allow for more effective and patient-friendly ODTs.

Orally Disintegrating Tablet Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.1% over the forecast period (2024-2032)

Based on Drug Type segmentation, the anti-allergic drugs segment was predicted to show maximum market share in the year 2023, owing to growing allergic disorders.

Based on Indication segmentation, the cardiovascular diseases segment was the leading Indication in 2023, owing to the high need for ODTs in cardiovascular therapies.

Based on Distribution Channel segmentation, the hospital pharmacies segment was the leading Distribution Channel segment in 2023, owing to the high demand for ODTs in hospitals.

Based on region, North America was the leading revenue generator in 2023, due to the growing prevalence of chronic diseases.

Orally Disintegrating Tablet Market- Segmentation Analysis:

The Global Orally Disintegrating Tablet Market is segmented based on Drug Type, Indication, Distribution Channel, and Region.

The market is divided into seven categories based on Drug Type: anti-psychotics, anti-epileptics, anti-hypertensives, anxiolytics, anti-allergic drugs, proton pump inhibitors, and others. The anti-allergic drugs segment dominates the market. The high prevalence of allergic diseases is growing the demand for anti-allergic tablets.

The market is divided into five categories based on Indication: neurological diseases, cardiovascular diseases, gastrointestinal diseases, allergic diseases, and others. The cardiovascular diseases segment dominates the market. ODTs are widely used for treating every cardiovascular disease which boosts segment growth.

The market is divided into three categories based on Distribution Channels: hospital pharmacies, online pharmacies, and others. The hospital pharmacies segment dominates the market and is expected to maintain its high dominance during the forecast period. The online pharmacies segment is estimated to grow at the fastest rate over the forecast period.

Orally Disintegrating Tablet Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America holds a significant share of the global ODT market, largely due to its advanced healthcare infrastructure and high prevalence of chronic diseases. The Asia-Pacific region is experiencing rapid growth in the ODT market due to rising healthcare access, increasing chronic disease prevalence, and a large patient population. Significant market opportunities in countries like India and China, are driven by high population density and increasing healthcare needs. There is also a growing trend towards domestic pharmaceutical companies developing ODT formulations.

Orally Disintegrating Tablet Market- Competitive Landscape:

The Orally Disintegrating Tablet (ODT) market is highly competitive, with several key players and ongoing developments shaping its landscape. Market players are developing new ODT formulations with improved taste-masking and faster disintegration times. Innovations in excipient technologies and tablet matrix design are enhancing the overall patient experience. Major pharmaceutical companies are focusing on expanding their ODT product offerings in emerging markets such as Asia-Pacific and Latin America. This expansion is driven by growing healthcare access and increasing demand for patient-friendly medication.

Recent Developments:

In March 2023, Zydus Cadilla got FDA approval for manufacturing Olanzapine ODT for nervous system diseases.

In June 2022, Catalent and MigVax announced the utilization of Zydis Bio orally disintegrating tablet technology.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ORALLY DISINTEGRATING TABLET MARKET KEY PLAYERS

GLOBAL ORALLY DISINTEGRATING TABLET MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019-2032

GLOBAL ORALLY DISINTEGRATING TABLET MARKET, BY INDICATION- MARKET ANALYSIS, 2019-2032

GLOBAL ORALLY DISINTEGRATING TABLET MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019-2032

GLOBAL ORALLY DISINTEGRATING TABLET MARKET, BY REGION- MARKET ANALYSIS, 2019-2032

Table of Contents

1. Orally Disintegrating Tablet Market Overview

2. Executive Summary

3. Orally Disintegrating Tablet Key Market Trends

4. Orally Disintegrating Tablet Industry Study

5. Orally Disintegrating Tablet Market: COVID-19 Impact Analysis

6. Orally Disintegrating Tablet Market Landscape

7. Orally Disintegrating Tablet Market - By Drug Type

8. Orally Disintegrating Tablet Market - By Indication

9. Orally Disintegrating Tablet Market - By Distribution Channel

10. Orally Disintegrating Tablet Market- By Geography

11. Key Vendor Analysis- Orally Disintegrating Tablet Industry

12. 360 Degree Analyst View

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â